

1 Seroprevalence of anti-SARS coronavirus 2 antibodies in 2 Thai adults during the first three epidemic waves

3
4 Hatairat Lerdsamran¹, Anek Mungaomklang², Sapon Iamsirithaworn³, Jarunee Prasertsopon¹,
5 Witthawat Wiriyarat⁴, Suthee Saritsiri⁵, Ratikorn Anusornatanawat⁶, Nirada Siriyakorn⁷, Poj
6 Intalapaporn⁷, Somrak Sirikhetkon², Kantima Sangsiriwut⁸, Worawat Dangsakul⁹, Suteema
7 Sawadpongpan¹, Nattakan Thinpan¹, Pilailuk Okada⁹, Ranida Techasuwan³, Noparat
8 Mongkalagoon³, Kriengkrai Prasert¹⁰, Pilaipan Puthavathana^{1*}

9
10 ¹ Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand

11 ² Institute for Urban Disease Control and Prevention, Department of Disease Control, Ministry of
12 Public Health, Bangkok, Thailand

13 ³ Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand

14 ⁴ Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, Thailand

15 ⁵ The 67th Public Health Center Thaweewatthana, Department of Health, Bangkok Metropolitan
16 Administration, Bangkok, Thailand

17 ⁶ Chaophraya Yommarat Hospital, Office of the Permanent Secretary, Ministry of Public Health,
18 Suphanburi, Thailand

19 ⁷ Rajavithi Hospital, Department of Medical Services, Ministry of Public Health, Bangkok,
20 Thailand

21 ⁸ Department of Preventive and Social Medicine, Faculty of Medicine Siriraj Hospital, Mahidol
22 University, Bangkok, Thailand

23 ⁹ Department of Medical Science, Ministry of Public Health, Nonthaburi, Thailand

24 ¹⁰ Nakhon Phanom Provincial Hospital, Department of Medical Services, Ministry of Public
25 Health, Nakhon Phanom, Thailand

26

27 *Corresponding author

28 E-mail: pilaipan.put@mahidol.edu (PP)

29

30 **Abstract**

31 This study sought to determine the anti-SARS-CoV-2 antibody status of 4111 Thai people from
32 May 2020 to April 2021, a period which spanned the first two and part of the third epidemic wave
33 of the COVID-19 in Thailand. Participants comprised 142 COVID-19 patients, 2113 individuals
34 at risk due to their occupations [health personnel, airport officers, public transport drivers, and
35 workers in entertainment venues (pubs, bars and massage parlors)], 1856 individuals at risk due to
36 sharing workplaces or living communities with COVID-19 patients, and 553 Thai citizens
37 returning after extended periods in countries with a high disease prevalence. All sera were tested
38 in a microneutralization assay and a chemiluminescence immunoassay (CLIA) for IgG against the
39 N protein. Furthermore, we performed an immunofluorescence assay to resolve discordant results
40 between the two assays. Antibody responses developed in 88% (15 of 17) of COVID-19 patients
41 at 8 days and in 94-100% between 15 and 60 days after disease onset. Neutralizing antibodies
42 persisted for at least 8 months, longer than the IgG did, against the N protein. None of the health
43 providers, airport officers, and public transport drivers were seropositive, while the antibodies
44 were present in 0.44% of entertainment workers. This study showed the seropositivity of 1.9, 1.5,
45 and 7.5% during the 3 epidemic waves, respectively, in Bangkok residents who were at risk due

46 to sharing workplaces or communities with COVID-19 patients. Also, antibody prevalence was
47 1.3% in Chiang Mai people during the first epidemic wave, and varied between 6.5 and 47.0% in
48 Thais returning from high-risk countries. This serosurveillance study found a low infection rate of
49 SARS-CoV-2 in Thailand before the emergence of the Delta variant in late May 2021. The findings
50 support the Ministry of Public Health's data, which are based on numbers of patients and contact
51 tracing.

52 **Key words:** SARS-coronavirus-2, seroepidemiology, microneutralization assay, ELISA,
53 chemiluminescence assay, immunofluorescence assay, Thailand

54

55 **Introduction**

56 On 13 January 2020, Thailand was the first country to report a confirmed coronavirus
57 disease-19 (COVID-19) case outside of China. The first indigenous case in Thailand occurred on
58 30 January 2020 in a local taxi driver who had no history of traveling abroad; investigation
59 suggested that he was exposed to the severe acute respiratory syndrome coronavirus-2 (SARS-
60 CoV-2) by a group of Chinese tourist passengers [1]. As of November 2021, Thailand had
61 experienced 4 epidemic waves associated with different SARS-CoV-2 variants which emerged
62 during the pandemic (Fig 1).

63

64 **Fig 1. Situation of SARS-CoV-2 infection in Thailand during March 1, 2020 through**
65 **December 21, 2021.**

66

67 According to the Department of Disease Control (DDC), Ministry of Public Health
68 (MOPH), the first epidemic wave began in January 2020, peaked in March-April, gradually

69 declined, and ended on 14 December 2020. Large clusters occurring during this wave had linkages
70 with attending boxing stadiums or entertainment venues in Bangkok. The strains causing this wave
71 belonged to clades L, S, O, V, and G likely reflecting multiple introductions of virus into the
72 country through tourism. The second wave was shorter, lasting from 15 December 2020 to 31
73 March 2021. This epidemic wave began among Myanmar migrant workers in a seafood market in
74 Mahachai District, Samut Sakorn Province, 37 km south of Bangkok. The causative virus belonged
75 to the GH clade (G614 mutation) which was circulating in Myanmar during the second epidemic
76 wave since August 2020 [2]. The third epidemic wave in Thailand began on 1 April 2021, again
77 in nightlife entertainment venues, and might be linked to the introduction of the Alpha variant
78 (B.1.1.7) by the Thai people returning from Cambodia in the middle of March 2021 [3]. The Alpha
79 variant had spread throughout Cambodia, particularly in Phnom Penh, since February 2021 [4].
80 The Alpha variant spread to many parts of Thailand in the second week of April due to movement
81 of large numbers of people during the annual Songkran or water festival (the traditional Thai new
82 year). Subsequently, the Delta variant, first detected among workers in a big construction camp at
83 Laksi, Bangkok, on 7 May 2021 [5], spread countrywide seeding the fourth epidemic wave and
84 caused loss of control of the epidemic.

85 People infected with SARS-CoV-2 may develop antibodies targeting multiple viral
86 proteins, regardless of whether they have symptoms or not. Therefore, serosurveillance was an
87 important tool for estimating the magnitude and monitoring the epidemic, especially since
88 asymptomatic cases were common. A meta-analysis showed that as many as 35% of cases were
89 asymptomatic [6]. Serological data can also show the duration of antibody responses to COVID-
90 19 infection, indicating partial protection from re-infection. Studies in Europe and the US have
91 shown that neutralizing antibodies persist in a majority of COVID-19 cases for up to 13 months

92 after infection [7], and patients with severe disease exhibited a higher level of neutralizing
93 antibodies than those with milder disease symptoms [8]. The present study conducted a cross-
94 sectional serosurveillance of anti-SARS-CoV-2 in Thai people in various risk groups in Bangkok
95 and Chiang Mai Province from May 2020 to May 2021 (the duration spanned the first, second,
96 and part of the third epidemic waves). The serological techniques used in this study included a
97 microneutralization (microNT) assay, a chemiluminescence immunoassay (CLIA), and an indirect
98 immunofluorescence assay (IFA).

99

100 **Material and methods**

101 **Ethical statement**

102 Usage of human sera from participants of age older than 18 received approval from the
103 Mahidol University Central Institutional Review Board (MU-CIRB) under protocol number MU-
104 COVID2020.001/2503.

105 **Study sites**

106 Bangkok, the capital of Thailand, and Chiang Mai Province, 696 km north of Bangkok,
107 were chosen as study sites due to their popularity as travel destinations, high population densities,
108 and the high numbers of SARS-CoV-2-infected cases.

109 **Study population**

110 The study involved 4111 serum samples from 4 groups of participants, as follows. 1)
111 Anonymized archival serum samples from COVID-19 patients with no information of disease
112 severity (Sera were the leftover samples from clinical laboratory investigations). 2) People at risk
113 due to their occupations (health personnel, airport drivers, public transport drivers, and workers in

114 entertainment venues (e.g., pubs, bars, and massage parlors). 3) People at risk due to sharing
115 workplaces or communities with COVID-19 patients. In the enrollment process for participants in
116 groups 2 and 3, epidemiologists explained the purpose of the study to obtain written consent for
117 interviewing about their demographics, occupation, workplace, residence, and general health
118 condition, including a donation of 5-8 ml of blood, with specimens labeled using ID codes. 4) Thai
119 citizens in state quarantines, when arrived Thailand after extended duties in countries with known
120 SARS-CoV-2 outbreaks. Blood specimens were collected for anti-SARS-CoV-2 antibody testing
121 [along with real-time reverse transcription-polymerase chain reaction (RT-PCR)] to support active
122 case surveillance activities conducted by the Institute for Urban Disease Control and Prevention
123 (IUDC), DDC, MoPH. For this group, an ethical review was waived under the authorization of the
124 DDC, MOPH, as part of the emergency public health response to the pandemic. Nevertheless,
125 participants received explanations and gave verbal consent.

126 **Cell and virus cultivation**

127 We cultivated Vero cells (African green monkey kidney cells - ATCC, CCL-81) in Eagle's
128 minimum essential medium (EMEM) (Gibco, NY) supplemented with 10% fetal bovine serum
129 (FBS) (Gibco, NY), penicillin, gentamycin, and amphotericin B. SARS-CoV-2 was isolated and
130 propagated in Vero cells maintained in EMEM supplemented with 2% FBS in a Biosafety
131 Laboratory Level-3 facility. Using the Reed-Muench method, we calculated the virus
132 concentration for 50% tissue culture infective dose (TCID₅₀) for further use in the microNT assay.

133 **Test viruses**

134 This study used 3 SARS-CoV-2 isolates as test viruses in the microNT assay. The purpose
135 of doing so was to match the circulating virus at the time of blood specimen collection. The SARS-
136 CoV-2 isolate designated hCoV-19/Thailand/MUMT-4/2020, clade O (GISAID accession number

137 EPI_ISL_493139) was used as the test virus for sera collected during the first epidemic wave,
138 while hCoV-19/Thailand/MUMT-13/2021, clade GH (GISAID accession number
139 EPI_ISL_6267810), and hCoV-19/Thailand/MUMT-36/2021, clade GRY (B.1.1.7) (GISAID
140 accession number EPI_ISL_6267895) were used as the test viruses for the second and third
141 epidemic waves, respectively.

142 **Experimental design**

143 This study employed the microNT assay and CLIA to detect anti-SARS antibodies in each
144 test serum. When results of the two assays were concordant, the test serum was considered positive
145 or negative for anti-SARS antibodies. In case of discordant results, the test serum was further
146 investigated by IFA.

147 **Microneutralization assay**

148 We used the cytopathic effect (CPE)-based MicroNT assay to determine levels of
149 neutralizing (NT) antibodies against SARS-CoV-2 in the test sera. The assay employed Vero cell
150 monolayers in 96-well microculture plates and SARS-CoV-2 at a final concentration of 100
151 TCID₅₀/100 µl as the test virus. The method followed those described in our previous studies [9,
152 10]. Briefly, the test serum was heat-inactivated and serially two-fold diluted from 1:10 to 1:1280.
153 A 60 µl volume of each serum dilution was mixed with 60 µl of the test virus at a concentration of
154 200 TCID₅₀/100 µl. After an hour of incubation at 37 °C, a 100 µl volume of the virus-serum
155 mixture was inoculated in duplicate into wells containing the Vero cell monolayer. The reaction
156 plates were incubated at 37 °C for 3 days before reading the results. We defined the NT antibody
157 titer as the highest reciprocal serum dilution that inhibited $\geq 50\%$ CPE in the wells inoculated with
158 the serum-virus mixture compared to wells with the uninfected cell control. A titer of 10 or greater
159 was considered positive for NT antibody.

160 **Chemiluminescence immunoassay**

161 CLIA using Architect auto-analyzer (Abbott Laboratories, USA) is the two-step, fully
162 automated immunoassay that qualitatively detected binding between the SARS-CoV-2
163 nucleoprotein (N) antigen coated on paramagnetic microparticles and human IgG in the test sera.
164 The assay required a minimal volume of 150 μ l of test serum to fill the reaction cup. Acridinium-
165 conjugated anti-human IgG bound the human IgG and then emitted chemiluminescence signals
166 quantitated as a relative light units (RLUs). It took about 1 hour to complete a test run. The level
167 of SARS-CoV-2 IgG was directly correlated to the amount of RLUs. An index value was
168 established based on the ratio between the RLU of the kit positive sample (S) and the calibrator
169 (C). A test serum with an S/C ratio ≥ 1.4 was considered positive for the SARS-CoV-2 IgG.

170 **Indirect immunofluorescence assay**

171 The IFA staining method was previously described [10]. The assay employed SARS-CoV-
172 2-infected Vero cells deposited on microscopic slides as the test antigens. To standardize the test
173 antigen given the lot-to-lot variation, 50-75% of the infected cells must express N and spike (S1)
174 proteins when stained with specific monoclonal antibodies (Sino Biological, Beijing, China).
175 Human serum at a dilution of 1:10 in phosphate-buffered saline was incubated with the infected
176 cell for 60 minutes at 37 °C and followed by addition of polyclonal rabbit anti-human IgA, IgG,
177 IgM, Kappa, and Lambda conjugated with fluorescein isothiocyanate (Dako, Glostrup, Denmark)
178 in Evan's blue solution for 60 minutes. The stained viral antigens in the cytoplasm of the infected
179 cells appeared apple green when examined under a fluorescence microscope.

180 **Statistical analysis**

181 R square (R^2), mean, and standard deviation (SD) were determined, and figures were drawn
182 using GraphPad Prism version 8.4.3 for Windows (GraphPad Software, La Jolla, California, USA).
183 The McNemar test was carried out and 95% confidence interval (95% CI) calculated by SPSS
184 Statistic software version 18.0.

185

186 **Results**

187 **Prevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients by** 188 **time**

189 Using microNT assay and Architect IgG, and IFA for confirmation, anti-SARS-CoV-2
190 antibodies were detected in 124 (87.3%) of 142 COVID-19 patients from the first epidemic wave.
191 Eighty-eight percent (15 of 17) of the patients had antibody responses at 8 days after onset of
192 symptoms. Positivity rose further to 94.1% (16 of 17) at 15-21 days, 100% (19 of 19) at 22-30
193 days, and 97% (32 of 33) at 31-60 days after onset of symptoms (Fig 2). NT antibodies persisted
194 for at least 8 months as found in all 7 participants with history of COVID-19, while IgG specific
195 to N protein was found in only 3 of these 7 cases. Nevertheless, the numbers of antibody-positive
196 cases detected by microNT assay and CLIA for IgG were not significantly different (McNemar
197 test; $p = 0.65$). On the other hand, the NT antibody titers were not well correlate with the IgG levels
198 ($R^2 = 0.6042$) (Fig 3).

199

200 **Fig 2. Antibody response in COVID-19 patients at different time points after onset of disease**
201 **symptoms.**

202 **Fig 3. Correlation between NT antibody titers and Architect IgG indices in COVID-19**
 203 **patients.**

204
 205 **Prevalence of anti-SARS-CoV-2 antibodies in participants with**
 206 **selected occupations**

207 The early COVID-19 outbreak in Thailand showed that some occupations had higher risk
 208 of infection than did others. We conducted serosurveillance for anti-SARS-CoV-2 antibodies in
 209 2113 participants with at-risk occupations (health personnel, airport officers, public transport
 210 drivers and workers in entertainment venues) as shown in Table 1. The serum samples from health
 211 personnel were collected during the three epidemic waves, while the others were collected from
 212 the first or second epidemic wave. The result showed that none of the 2113 participants had anti-
 213 SARS-CoV-2 antibodies, except for 3 (0.44%) of 682 workers from the entertainment venues.

214
 215 **Table 1. Seroprevalence of anti-SARS-CoV-2 antibodies in participants with at-risk**
 216 **occupations.**

Group	Epidemic wave			Subtotal
	Jan – December 14, 2020	December 15, 2020 – March 31, 2021	April 1 – May 31, 2021	
	No. pos/ No. tested	No. pos/ No. tested	No. pos/ No. tested	
Health personnel	0/187	0/13	0/272	0/472
Airport officers	0/493	-	-	0/493
Public transport drivers	0/455	0/11	-	0/466
Entertainment workers	3/682	-	-	3/682 (0.44%) 95% CI = 0.08 – 1.29%
Total = 3/2113 (0.14%), 95% CI = 0.03 – 0.42%				

217

218 **Prevalence of anti-SARS-CoV-2 antibodies in people at risk**

219 We conducted serosurveillance in 1856 Thai people at risk by sharing the same workplaces
 220 or living in the same community with COVID-19 cases. The investigation showed that 1.9% (11
 221 of 574), 1.5% (6 of 388), and 7.5% (11 of 147) of people in Bangkok were seropositive for anti-
 222 SARS-CoV-2 antibody during the three epidemic waves, respectively. In Chiang Mai, 1.3% (10
 223 of 747) of participants were seropositive during the first epidemic wave; 7 of them provided
 224 histories of having COVID-19 during the prior 8 months (Table 2).

225

226 **Table 2. Seroprevalence of anti-SARS-CoV-2 antibodies in participants who shared**
 227 **workplaces or lived in communities with reported COVID-19 cases.**

Province	Epidemic wave		
	Jan – December 14, 2020	December 15, 2020 – March 31, 2021	April 1 – May 31, 2021
	No. pos/No. tested	No. pos/No. tested	No. pos/No. tested
Bangkok	11/574 (1.9%) 95% CI = 0.95 – 3.43%	6/388 (1.5%) 95% CI = 0.56 – 3.37%	11/147 (7.5%) 95% CI = 3.72 – 13.40%
Chiang Mai	10/747 (1.3%) 95% CI = 0.64 – 2.46%	-	-
Subtotal	21/1321(1.6%) 95% CI = 0.98 – 2.43%	6/388 (1.5) 95% CI = 0.56 – 3.37%	11*/147 (7.5%) 95% CI = 3.72 – 13.40%
Total = 38/1856 (2.04%), 95% CI = 1.44 – 2.81%			

228 * 7 participants provided history of COVID-19 at 8 months previously

229

230 **Serological profiles of anti-SARS-CoV-2 antibodies in participants at**
231 **risk**

232 We display in Tables 1 and 2 the serological profiles of anti-SARS-CoV-2 antibodies in
233 3969 participants, grouped as 2113 people at risk by occupation (Table 1), and 1856 people at risk
234 by sharing workplaces or living community with COVID-19 patients. Using microNT assay and
235 Architect IgG, followed by IFA validation, 41 of 3969 (1.0%) were seropositive for anti-SARS-
236 CoV-2 antibodies. The number of seropositive cases detected by Architect IgG was slightly lower
237 than that detected by microNT, but not significantly different (McNemar test; $p = 0.54$).
238 Furthermore, the NT antibody titers were not well correlated with the IgG levels obtained by CLIA
239 ($R^2 = 0.5908$) (Fig 4).

240

241 **Fig 4. Correlation between NT antibody titers and Architect IgG indices in Thai people.**

242

243 **Prevalence of anti-SARS-CoV-2 antibody in travelers returning from**
244 **high-risk areas**

245 This study conducted serosurveillance in 553 Thai citizens returning after extended duties
246 in countries with high-prevalence of SARS-CoV-2 infection between May and October 2020. Our
247 results showed seroprevalences of 6.5 – 47.0% depending on the country (Table 3).

248

249 **Table 3. Seroprevalence of anti-SARS-CoV-2 antibodies in Thais returning from extended**
250 **periods of work in high-risk countries.**

Country	Date of blood collection	No. pos/No. tested (%)
Qatar	May - Jun 2020	14/215 (6.5%) 95% CI = 3.55 – 10.93%
Kuwait	May - Jun 2020	101/215 (47.0%) 95% CI = 38.27 – 57.08%
Sudan	Oct 2020	36/77 (46.8%) 95% CI = 32.75 – 64.72%
Others	Jun - Oct 2020	4/46 (8.7%) 95% CI = 2.28 – 22.36%
Total = 155/553 (28.0%), 95% CI = 23.79 – 32.80%		

251

252

253 **Discussion**

254 We employed 3 serological techniques to detect anti-SARS-CoV-2 antibodies in this
255 cross-sectional surveillance study. The NT antibodies were directed against the neutralizing
256 epitopes present in the receptor-binding domain (RBD), N terminal domain (NTD), and S2 domain
257 in the S protein [11-15]; Architect IgG was directed against the N antigen which is a more
258 conserved protein [16, 17]. NT antibodies are markers of protective immunity, but IgG against N
259 protein is not. MicroNT assay and Architect IgG were used to investigate every serum sample, and
260 the result was concluded to be negative when both methods yielded concordant results. In the case
261 of discordant results, IFA (which employed the test antigens from both the S and N proteins) was
262 used to resolve discordance. Overall, the numbers of seropositive participants determined by

263 microNT assay and Architect IgG were not significantly different. Nevertheless, NT antibody titers
264 were not well correlated with the IgG levels.

265 Our study in COVID-19 patients showed that 15 of 17 (88.2%) patients mounted a
266 detectable antibody response 8-14 days after onset of symptoms. However, the prevalence
267 increased to as high as 94-100% in the subsequent 45 days. In addition, we found that anti-SARS-
268 CoV-2 antibodies persisted for at least 8 months in all 7 individuals who had a history of COVID-
269 19, while Architect IgG to N protein did not last that long. This is similar to the findings of others
270 who reported 8-month antibody persistence in mild SARS-CoV-2 infections [18] and up to one
271 year in one study [19].

272 We investigated 3969 blood samples from multiple groups of participants between May
273 14, 2020 and May 21, 2021, the duration spanning two epidemic waves and part of the third wave.
274 Of 2113 participants with the at-risk occupations (472 health providers, 493 airport officers, 466
275 public transport drivers, and 682 workers in entertainment venues), only 0.14% (all 3 from the last
276 group) had detectable anti-SARS-CoV-2 antibodies. Furthermore, of 1856 participants who shared
277 workplaces or communities, only 38 (2.04%) were seropositive. Over time, the number of
278 participants in Bangkok who had anti-SARS-CoV-2 antibodies increased from 1.9 to 1.5 and 7.5%
279 during the 3 epidemic waves, respectively. Our seroprevalence data strongly supported the
280 prevalence of infection reported by the MoPH, i.e., the cumulative numbers of 4237 cases with 60
281 deaths at the end of the first epidemic wave (from Jan to Dec 14, 2020), 28863 cases with 94 deaths
282 at the end of the second epidemic wave (from Dec 15, 2020 to Mar 31, 2021), and 159792 cases
283 with 1031 deaths (from Apr 1 to May 31, 2021).

284 Thailand received worldwide recognition for keeping the first epidemic wave well
285 controlled. During the first epidemic wave, cumulative case count per population was in the 10th

286 percentile of countries globally [20]. As part of the control policy, the government provided
287 treatment and hospitalization, quarantine, and laboratory diagnosis of SARS-CoV-2 infection at
288 no cost. The prevalence of infection during the wave peaked in March 2020, followed by a sharp
289 decline. None or less than 10 locally transmitted cases were detected daily from the middle of May
290 through the end of the first epidemic wave. In total, there were 4237 cases with 60 deaths by the
291 end of the first epidemic wave (December 14, 2020). The high seroprevalence (6.5 – 47%) in Thai
292 citizens returning from abroad suggested the seriousness of the outbreaks in those regions.
293 Nevertheless, high infection rates may be partly due to sharing workplaces among these
294 participants.

295 Management of non-pharmaceutical interventions in Thailand was efficient. No people
296 protested against wearing masks in public. They followed the suggestions on soft locked down,
297 social distancing, working from home, and personnel hygiene. A vital success came from the
298 assistance of approximately one million village health volunteers who are part of the public health
299 system and worked nationwide since the time of H5N1 avian influenza. These volunteers assist
300 with health education, active case finding, and communication between health authorities and
301 communities. For example, each volunteer is assigned to take care of approximately 10 houses.
302 Nevertheless, the occurrence of the second and third epidemic waves came very abruptly, from
303 introduction of the newer variants, the GH clade and the Alpha variant, respectively. We cannot
304 deny that these outbreaks due to illegal activities, including cross border movement of migrant
305 workers and gamblers.

306 Before the third epidemic wave trended down, the outbreak situation of SARS-CoV-2
307 became worse due to introduction of the Delta variant (that is more transmissible and virulent) to
308 seed a fourth epidemic wave. The infection rate peaked in August 2021, when more than 20000

309 cases were reported daily for weeks before slowly declining. However, non-pharmaceutical
310 intervention appears inadequate to control the Delta variant, and access to vaccines has not been
311 easy. The MoPH first launched vaccinations for health providers in late February 2021.

312 At present, seroprevalence studies in the Thai population will encounter difficulties in
313 differentiating between natural infection and vaccination. Nevertheless, our seroprevalence data
314 validate the reported lack of circulation of SARS-CoV-2 in Thailand during the first year of the
315 pandemic.

316

317 **Acknowledgements**

318 We thank Abbott Laboratories for providing Chemiluminescence test kits. We also thank
319 Chinda Kanoksinsombat, Tipsuda Chanmanee, Rumporn Kularb, and Charlearnsak Thapyotha for
320 laboratory assistance.

321

322 **References**

- 323 1. Sirilak S, editor. Thailand's experience in the COVID-19 response [Internet]. Ministry of
324 Public Health, Thailand. Aug 2020 [Cited 2021 October 31]. Available from:
325 <https://ddc.moph.go.th/viralpneumonia/eng/file/pubdoc/LDoc9.pdf>.
- 326 2. Win A. Rapid rise of COVID-19 second wave in Myanmar and implications for the Western
327 Pacific region. *QJM*. 2020;113:856-57.
- 328 3. Cheepsattayakorn A, Cheepsattayakorn R, Siriwanarangsun P. New waves of COVID-19 in
329 Thailand, Cambodia and Myanmar. *Am J Intern Med*. 2021;9: 114-20.

- 330 4. WHO Cambodia. Cambodia Coronavirus Disease 2019 (COVID-19) Situation Report #35.
331 2021 March 01 [Cited 2021 October 31]. Available from:
332 [https://www.who.int/cambodia/internal-publications-detail/covid-19-joint-who-moh-situation-](https://www.who.int/cambodia/internal-publications-detail/covid-19-joint-who-moh-situation-report-35)
333 [report-35](https://www.who.int/cambodia/internal-publications-detail/covid-19-joint-who-moh-situation-report-35).
- 334 5. Tribune B. First local cases of contagious Indian variant discovered among construction
335 workers in Lak si. Bangkok Tribune Online News Agency. 2021 May 21 [Cited 2021 October
336 31]. Available from: [https://bkktribune.com/first-local-cases-of-contagious-indian-variant-](https://bkktribune.com/first-local-cases-of-contagious-indian-variant-discovered-among-construction-workers-in-lak-si/)
337 [discovered-among-construction-workers-in-lak-si/](https://bkktribune.com/first-local-cases-of-contagious-indian-variant-discovered-among-construction-workers-in-lak-si/).
- 338 6. Sah P, Fitzpatrick MC, Zimmer CF, Abdollahi E, Juden-Kelly L, Moghadas SM, et al.
339 Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis. *Proc Natl Acad*
340 *Sci U S A*. 2021;118:e2109229118.
- 341 7. Gallais F, Gantner P, Bruel T, Velay A, Planas D, Wendling MJ, et al. Evolution of antibody
342 responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. *EBioMedicine*.
343 2021;71:103561.
- 344 8. Legros V, Denolly S, Vogrig M, Boson B, Siret E, Rigaille J, et al. A longitudinal study of
345 SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and
346 COVID-19 severity. *Cell Mol Immunol*. 2021;18:318-327.
- 347 9. Lerdsamran H, Prasertsopon J, Mungaomklang A, Klinmalai C, Noisamdaeng P, Sangsiriwut
348 K, et al. Seroprevalence of antibodies to enterovirus 71 and coxsackievirus A16 among people
349 of various age groups in a northeast province of Thailand. *Virol J*. 2018;15:158.
- 350 10. Lerdsamran H, Mungaomklang A, Iamsirithaworn S, Prasertsopon J, Prasert K, Intalapaporn P,
351 et al. Evaluation of different platforms for the detection of anti-SARS coronavirus-2 antibodies,
352 Thailand. *BMC Infect Dis*. 2021;21:1213.

- 353 11. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, et al. The
354 receptor-binding domain of the viral spike protein is an immunodominant and highly specific
355 target of antibodies in SARS-CoV-2 patients. *Sci Immunol.* 2020;5:eabc8413.
- 356 12. Brouwer PJM, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, et al. Potent
357 neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. *Science.*
358 2020;369:643-50.
- 359 13. Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, et al. A neutralizing human antibody binds
360 to the N-terminal domain of the Spike protein of SARS-CoV-2. *Science.* 2020;369:650-55.
- 361 14. Keng CT, Zhang A, Shen S, Lip KM, Fielding BC, Tan TH, et al. Amino acids 1055 to 1192 in
362 the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing
363 antibodies: implications for the development of vaccines and antiviral agents. *J Virol.*
364 2005;79:3289-96.
- 365 15. Yang H, Rao Z. Structural biology of SARS-CoV-2 and implications for therapeutic
366 development. *Nat Rev Microbiol.* 2021;19:685-700.
- 367 16. Dutta NK, Mazumdar K, Gordy JT. The Nucleocapsid Protein of SARS-CoV-2: a Target for
368 Vaccine Development. *J Virol.* 2020;94:e00647-20.
- 369 17. Negara MRM, Krissanti I, Pradini GW. Analysis of SARS-CoV-2 nucleocapsid protein
370 sequence variations in ASEAN countries. *Med J Indones.* 2021;30:89-95.
- 371 18. Perez-Saez J, Zaballa ME, Yerly S, Andrey DO, Meyer B, Eckerle I, et al. Persistence of anti-
372 SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance.
373 *Clin Microbiol Infect.* 2021;27:1695.e7-12.

374 19. Haveri A, Ekström N, Solastie A, Virta C, Österlund P, Isosaari E, et al. Persistence of
375 neutralizing antibodies a year after SARS-CoV-2 infection in humans. *Eur J Immunol.*
376 2021;51:3202-13.

377 20. Our World in Data. Thailand: Coronavirus Pandemic Country Profile. 2021 [Cited 2021
378 October 20]. Available from: <https://ourworldindata.org/coronavirus/country/thailand>.

379

380






Fig2



NT antibody titer	<10	10	20	40	80	160	320	640	No. pos/Total (%)
Number of cases	20	15	32	12	24	15	13	11	122/142 (85.9)
Number positive by Architect IgG (%)	2 (10.0)	10 (66.7)	30 (93.8)	11 (91.7)	23 (95.8)	15 (100.0)	13 (100.0)	11 (100.0)	115/142 (81.0)
Mean of index values (S/C)	0.53	1.9	3.8	4.8	5.2	6.3	7.4	7.6	4.4

Fig3



NT antibody titer
Number of cases

<10
3928

10
9

20
9

40
12

80
7

160
4

No. pos/Total (%)
41/3969 (1.0)

Number positive by Architect IgG
(%)

10
(0.3)

4
(44.4)

4
(44.4)

9
(75.0)

6
(85.7)

4
(100.0)

37/3969
(0.9)

Mean of index values (S/C)

0.07

2.7

2.4

3.6

4.4

7.1

0.11

Fig4




Fig1